WallStSmart

AnaptysBio Inc (ANAB)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AnaptysBio Inc generates 31219% more annual revenue ($232.39M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -11.5%. RVMD earns a higher WallStSmart Score of 24/100 (F).

ANAB

Avoid

21

out of 100

Grade: F

Growth: 5.3Profit: 3.0Value: 6.7Quality: 5.0
Piotroski: 4/9Altman Z: -0.80

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ANABUndervalued (+85.7%)

Margin of Safety

+85.7%

Fair Value

$385.19

Current Price

$50.37

$334.82 discount

UndervaluedFair: $385.19Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ANAB0 strengths · Avg: 0/10

No standout strengths identified

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

ANAB4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.56B3/10

Smaller company, higher risk/reward

Price/BookValuation
114.5x2/10

Trading at 114.5x book value

Return on EquityProfitability
-210.1%2/10

ROE of -210.1% — below average capital efficiency

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ANAB

ANAB has a balanced fundamental profile.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : ANAB

The primary concerns for ANAB are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 21.76 is elevated, increasing financial risk.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

ANAB profiles as a turnaround stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

ANAB is growing revenue faster at -8.0% — sustainability is the question.

ANAB generates stronger free cash flow (-26M), providing more financial flexibility.

Bottom Line

RVMD scores higher overall (24/100 vs 21/100). ANAB offers better value entry with a 85.7% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AnaptysBio Inc

HEALTHCARE · BIOTECHNOLOGY · USA

AnaptysBio, Inc., a clinical-stage biotechnology company, is dedicated to developing therapeutic product candidates for inflammation and immuno-oncology indications. The company is headquartered in San Diego, California.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?